NEW YORK – Parsippany, New Jersey-based Interpace Diagnostics announced today that it has signed a contract with Blue Cross Blue Shield of Michigan to cover its ThyGeNext and ThyraMir thyroid cancer detection assays as an in-network service, limiting the insurer's members' out-of-pocket expenses.
Blue Shield Blue Cross of Michigan, a member of the Blue Cross Blue Shield Association, covers about 4.5 million members in Michigan and another 1.6 million members across other states.
The ThyGeNext and ThyraMir tests are used to determine the presence or absence of cancer in thyroid nodules. According to Interpace, the ThyGeNext-ThyraMir combination uses next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier to offer physicians actionable test results.
"This contract, with one of the largest BCBS plans in the country, represents another milestone in solidifying our molecular thyroid products' place in the market," Interpace CEO Jack Stover said in a statement.
Interpace said earlier this week that Blue Shield of California agreed to cover its thyroid tests.